EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA ‐4359 for Use in First‐In‐Human Trials

Stephen A. Greene, Madhav Channavazzala, Bhairav Paleja, Harshbir Singh Sandhu, Rukmini Kumar, Husain Attarwala, Linh Van, Min Liang

CPT: Pharmacometrics & Systems Pharmacology · 2026-02 · 15 (2)

DOI: 10.1002/psp4.70188 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT The investigational antigen‐specific immunotherapy mRNA‐4359 is a lipid nanoparticle–encapsulated mRNA‐based immunotherapy that encodes for the immunogenic indoleamine 2,3‐dioxygenase (IDO) and programmed death‐ligand 1 (PD‐L1) antigens. An ongoing first‐in‐human (FIH) phase 1/2 clinical trial (NCT05533697) will evaluate the safety and antitumor activity of mRNA‐4359 when administered alone and in combination with the anti–programmed death‐1 agent pembrolizumab in participants with advanced solid tumors. The current analysis applied a novel immunostimulatory/immunodynamic (IS/ID) modeling approach to determine a plausible starting dose of mRNA‐4359 for the FIH trial. The model used for the FIH dose prediction was calibrated to previously published clinical trial data obtained for an immunomodulatory peptide‐based vaccine activating IDO‐ and PD‐L1–specific T cells in patients with metastatic melanoma. The analysis found that a 180 μg dose of mRNA‐4359 would possibly elicit a T‐cell response similar to a 200 μg dose of the peptide‐based vaccine with a range of 45–360 μg, assuming a potential 4‐fold higher to 2‐fold lower efficiency (the ability to elicit IFN‐γ secreting T cells, indicative of cytotoxic potential). Model simulations further predicted that a 15‐cycle every 3 weeks regimen of mRNA‐4359 could be expected to provide longer responses than other feasible simulated regimens. Finally, the IS/ID modeling analysis determined that a 100 μg dose of mRNA‐4359 would be the most appropriate starting dose for FIH trials. The described approach represents a unique application of IS/ID modeling to determine a therapeutically relevant FIH starting dose in the absence of supporting preclinical animal data.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →